Rat Models of Wet AMD in the MICRON Literature
About the MICRON Research Literature
These research pages organize published studies using MICRON imaging systems by animal species and the disease or condition investigated.
All publication counts and figures reflect the complete indexed research collection.
Explore related studies through the MICRON Research Hubs or search the complete publication collection in the reSEARCH portal.
Understanding Wet AMD
Neovascular AMD is a human disease of the macula, involving new vessel growth that most commonly arises from the choroid, either remaining beneath the retinal pigment epithelium or entering the subretinal space, with a third form originating in the retinal circulation.
Where the vessels leak, that leakage is directly imageable, which is why angiography recurs as a readout in this literature.
Wet AMD in Experimental Research
The species here have no macula, so this work models components of neovascular AMD, most directly the neovascular process, without reproducing the macular anatomy of the human disease.
In much of this literature choroidal neovascularization is induced by laser and read out in a non-macular retina.
Rat Models of Wet AMD
The rat offers a larger eye than the mouse while remaining a small-animal model, which eases injection and imaging without moving to a large species.
Published MICRON Research: Wet AMD in Rats
This page lists 12 papers from the MICRON literature, published 2013 to 2025, that study neovascular (wet) age-related macular degeneration in rats.
Of these publications:
- 11 studies used rats as the primary wet age-related macular degeneration disease model.
- 1 study used healthy animals to assess pharmacokinetics, drug delivery, or tolerability.
Scope of the literature collection: Publication counts reflect studies identified and indexed in the MICRON research corpus. This collection is not intended to represent an exhaustive review of all published wet age-related macular degeneration research.
Which imaging and experimental techniques are used in these studies?
| Technique | Papers |
|---|---|
| Intravitreal Injection / Delivery | 11 |
| Fundus Fluorescein Angiography | 10 |
| Optical Coherence Tomography | 5 |
| Topical Ophthalmic Drug Delivery | 4 |
| AAV-Mediated Ocular Gene Delivery | 2 |
| Laser Photocoagulation Models | 2 |
| Electroretinography | 1 |
| Ocular Implants / Sustained Release | 1 |
Technique counts are paper-level co-occurrences and do not necessarily indicate that a technique was applied to the focal species or focal disease model.
Capabilities and Limitations of Imaging Techniques
A summary of what each imaging technique listed above can measure, the information it provides, and its limitations in research applications.
Intravitreal Injection / Delivery
Injection into the vitreous places a substance directly into the vitreous at a known administered dose and chosen time, reducing but not eliminating systemic exposure. The injectate may be a therapeutic compound, cell preparation or viral vector, or an agent used to create the model, such as a toxin, vasoactive or excitotoxic compound, or infectious inoculum. The route bypasses surface-delivery barriers and provides direct access to the vitreous and posterior segment, but the concentration reached in a particular ocular tissue depends on distribution and clearance and is not fixed by the injected dose alone. It is invasive and discrete: each repeat dose or challenge requires another injection, and vehicle- or sham-injected controls can help separate effects of the injectate from effects of the procedure.
Fundus Fluorescein Angiography
Fundus fluorescein angiography uses an injected fluorescent dye to visualize blood flow through the retinal and choroidal circulation. Sequential images show how vessels fill, identify areas of reduced or absent perfusion, and reveal dye leakage associated with vascular abnormalities.
This technique is particularly useful for evaluating vascular perfusion, blood-retinal barrier integrity, and abnormal vessel growth. Fluorescein angiography primarily shows dye distribution rather than the surrounding retinal tissue. It provides a two-dimensional (en face) view in which vessels at different depths may overlap. Cross-sectional and cellular structural details require other imaging methods, such as optical coherence tomography (OCT) or optical coherence tomography angiography (OCT-A). Vascular abnormalities that do not affect dye filling or produce leakage may also remain undetected.
Optical Coherence Tomography
Optical coherence tomography provides high-resolution, cross-sectional images of ocular tissues in the living eye, allowing researchers to visualize structures at different depths. OCT is particularly useful for measuring tissue thickness, identifying structural abnormalities, and assessing the location and extent of tissue changes.
As a non-invasive imaging technique, OCT enables repeated measurements in the same eye over time, supporting longitudinal studies of disease progression and treatment response. Although OCT provides detailed structural information, it does not directly measure cellular activity or visual function. Tissue that appears structurally normal may still have functional abnormalities, making OCT a valuable companion to functional assessments such as electroretinography (ERG).
Topical Ophthalmic Drug Delivery
A compound applied as drops to the ocular surface. It is non-invasive and repeatable, so it supports frequent dosing without a procedure for each dose. What the route has to establish depends on the target: for an ocular-surface target, residence time and penetration into the surface tissue are the main barriers; for an intraocular anterior-segment target, the compound must cross ocular-surface and corneal or conjunctival barriers and reach an intraocular concentration sufficient for the experiment; for a posterior-segment target, additional ocular barriers separate the surface from the target and posterior-segment exposure is harder to establish.
AAV-Mediated Ocular Gene Delivery
An adeno-associated viral vector delivers genetic material to ocular cells, and a single administration can support long-lived transgene expression. That persistence is useful for gene augmentation and sustained therapeutic-protein expression; AAV can also deliver gene-silencing or genome-editing cargo, where long-lived expression of the editing machinery may be unnecessary or undesirable. Capsid and route of delivery jointly determine which cells are reached, so different delivery routes and vector designs give different distributions.
Laser Photocoagulation Models
A laser lesion provokes a reproducible, quantifiable injury at a known time and place. Wavelength, power, duration, spot size, pulse mode, focus and lesion location together determine the injury produced, allowing laser exposure to be configured for different experimental endpoints. It is an induced injury, not the disease: it produces a lesion directly, bypassing the process that gives rise to comparable damage in patients.
Electroretinography
Records the retina's electrical response to light, giving component-sensitive information about outer- and inner-retinal function. It measures function directly, which no structural method does. Full-field ERG sums across the whole retina, so a small lesion can leave the trace unchanged; focal and multifocal variants trade signal amplitude for spatial resolution.
Ocular Implants / Sustained Release
A sustained-release system holds a compound in or on the eye and lets it out gradually, so exposure is maintained from one placement rather than from a series of doses. The class spans polymer and non-polymer solid depots, injectable and particulate carriers, and reservoir devices; the release period belongs to the platform and not to the route, and runs from days to years. What the approach is for is to separate the dosing interval from the procedure interval, holding exposure at the target for as long as the question runs, whether that is the few weeks of a short-lived model or the span of a lifelong disease, without an intervention for each dose. What it gives up is control after placement. The release profile has to be measured rather than assumed, altering or ending delivery may require a further procedure, biodegradable systems behave differently from removable ones, and the carrier sits in contact with ocular tissue, so how the eye tolerates it is part of the result and not a precondition of it.
Which MICRON systems and add-ons appear?
| Instrument | Papers |
|---|---|
| MICRON III | 7 |
| MICRON IV | 6 |
| Image-Guided OCT | 3 |
| Image-Guided Laser | 2 |
Which strains and genetic lines are used?
| Strain | Papers | Reported as |
|---|---|---|
| Brown Norway | 9 | |
| Lister hooded | 1 | |
| Long-Evans | 1 | |
| Sprague-Dawley | 1 | SD |
Which other species appear alongside?
| Species | Papers |
|---|---|
| Mouse | 6 |
| Rabbit | 2 |
| Cynomolgus Macaque | 1 |
| Swine / Domestic Pig | 1 |
What other conditions are recorded on the same papers?
| Disease | Papers |
|---|---|
| Age-Related Macular Degeneration (General) | 11 |
| Choroidal Neovascularization | 10 |
| Retinal Neovascularization (General) | 3 |
| Age-Related Macular Degeneration (Dry/Atrophic) | 1 |
| Corneal Neovascularization | 1 |
| Multiple Sclerosis (Retinal Involvement) | 1 |
| Retinal Degeneration (General) | 1 |
| Retinitis Pigmentosa (RP) | 1 |
Which MICRON configurations appear in this work?
Configurations recorded in these papers, and the techniques recorded alongside them.
| MICRON configuration | Papers | Most frequent techniques recorded alongside |
|---|---|---|
| MICRON III | 7 | Fundus Fluorescein Angiography (6), Intravitreal Injection / Delivery (6), Optical Coherence Tomography (3) |
| MICRON IV | 6 | Intravitreal Injection / Delivery (6), Fundus Fluorescein Angiography (5), Optical Coherence Tomography (3) |
| Image-Guided OCT | 3 | Fundus Fluorescein Angiography (3), Intravitreal Injection / Delivery (3), Optical Coherence Tomography (2) |
| Image-Guided Laser | 2 | Intravitreal Injection / Delivery (2), AAV-Mediated Ocular Gene Delivery (1), Fundus Fluorescein Angiography (1) |
The papers
| Year | Title | Journal | Role of focal species | MICRON products | Links |
|---|---|---|---|---|---|
| 2025 | Acriflavine delivery via Polyurethane nanocapsules to treat neovascular age-related macular degeneration | bioRxiv | Disease model | Image-Guided OCT, MICRON IV | DOI · reSEARCH |
| 2025 | Development of a humanized anti-fibrin monoclonal antibody for the treatment of neuroinflammatory and retinal diseases. | Journal of Neuroinflammation | Disease model | MICRON IV | DOI · reSEARCH |
| 2025 | OBM1701 Alleviates Choroidal Neovascularization in Experimental Animals Via Suppressing the Expression of HIF-1α in Retinal Pigment Epithelial Cells. | Translational Vision Science & Technology | Disease model | MICRON III | DOI · reSEARCH |
| 2023 | Systemic Dendrimer-Peptide Therapies for Wet Age-Related Macular Degeneration. | Pharmaceutics | Disease model | Image-Guided Laser, MICRON III | DOI · reSEARCH |
| 2023 | An intravitreal-injectable hydrogel depot doped borneol-decorated dual-drug-coloaded microemulsions for long-lasting retina delivery and synergistic therapy of wAMD. | Journal of Nanobiotechnology | Healthy PK, delivery or tolerability | MICRON IV | DOI · reSEARCH |
| 2023 | Lentiviral delivered aflibercept OXB-203 for treatment of neovascular AMD. | Molecular Therapy. Methods & Clinical Development | Disease model | Image-Guided Laser, MICRON IV | DOI · reSEARCH |
| 2022 | Successful Proof-of-Concept for Topical Delivery of Novel Peptide ALM201 with Potential Usefulness for Treating Neovascular Eye Disorders. | Ophthalmology Science | Disease model | Image-Guided OCT, MICRON IV | DOI · reSEARCH |
| 2021 | A Novel Eye Drop Formulation for Potential Treatment of Neovascular Age-Related Macular Degeneration. | Translational Vision Science & Technology | Disease model | Image-Guided OCT, MICRON III, MICRON IV | DOI · reSEARCH |
| 2018 | VEGF/VEGFR2 blockade does not cause retinal atrophy in AMD-relevant models. | JCI Insight | Disease model | MICRON III | DOI · reSEARCH |
| 2017 | Therapeutic Effects of PPARα Agonist on Ocular Neovascularization in Models Recapitulating Neovascular Age-Related Macular Degeneration. | Investigative Ophthalmology & Visual Science | Disease model | MICRON III | DOI · reSEARCH |
| 2015 | A Quantitative and Standardized Method for the Evaluation of Choroidal Neovascularization Using MICRON III Fluorescein Angiograms in Rats. | PLoS ONE | Disease model | MICRON III | DOI · reSEARCH |
| 2013 | Silibinin inhibits VEGF secretion and age-related macular degeneration in a hypoxia-dependent manner through the PI-3 kinase/Akt/mTOR pathway. | British Journal of Pharmacology | Disease model | MICRON III | DOI · reSEARCH |
Browse all hubs at MICRON Research Hubs. The full corpus is searchable in the reSEARCH portal.